Moderna Wins FDA Approval for 2026-27 COVID Vaccines
Cambridge, Massachusetts, August 27, 2026 Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved supplemental...
Vaccine Safety
Advertisement
Vaxart Reports Positive 12-Month Phase 2b Safety Data
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Vaxart, Inc. has announced positive topline 12-month safety results from the approximately...
GC Biopharma’s Recombinant Anthrax Vaccine Shows Strong Phase 2 Safety and Efficacy Results
Yongin, South Korea — November 3, 2025 GC Biopharma has announced promising Phase 2 clinical trial results for its...
Pfizer and BioNTech Report Strong Data for LP.8.1-Adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)...
Novavax’s Nuvaxovid™ 2025–2026 Formula COVID-19 Vaccine Approved in the U.S.
GAITHERSBURG, Md., August 27, 2025 – The U.S. Food and Drug Administration (FDA) has granted approval for Novavax’s Nuvaxovid™...
Advertisement
